Literature DB >> 2904232

Pharmacodynamics of vecuronium and atracurium in the obese surgical patient.

J A Weinstein1, R S Matteo, E Ornstein, A E Schwartz, M Goldstoff, G Thal.   

Abstract

The effect of obesity on the duration of action of the nondepolarizing muscle relaxants atracurium and vecuronium was studied in 28 neurosurgical patients. In obese patients given vecuronium (0.1 mg/kg), the time to go from 5 to 25% of recovery of twitch response was statistically significantly longer (14.6 +/- 7 minutes, mean +/- SD) than it was in nonobese control patients (6.9 +/- 2 minutes). Similarly, with vecuronium times for recovery from 25 to 75% were longer (33 +/- 15 minutes) in obese patients than in control patients (13.2 +/- 2 minutes), as was time to 75% recovery, 82 +/- 30 minutes in obese patients, 50 +/- 9 minutes in controls. In contrast, obese patients given atracurium (0.5 mg/kg) exhibited no difference in recovery indexes or recovery times when compared to control patients of normal weight. The prolonged duration of action of vecuronium in obese patients is most likely related to impaired hepatic clearance and/or an overdose effect with recovery occurring during the distribution phase. That the duration of action of atracurium is not prolonged in the obese is believed due to this relaxant's not depending on organ function for elimination.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2904232

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients.

Authors:  Simone van Kralingen; Ewoudt M W van de Garde; Catherijne A J Knibbe; Jeroen Diepstraten; Marinus J Wiezer; Bert van Ramshorst; Eric P A van Dongen
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

2.  Anesthetic Pharmacology and the Morbidly Obese Patient.

Authors:  Jerry Ingrande; Hendrikus Jm Lemmens
Journal:  Curr Anesthesiol Rep       Date:  2012-12-13

3.  Onset of vecuronium neuromuscular block is more rapid in patients undergoing caesarean section.

Authors:  A Baraka; S Jabbour; Z Tabboush; A Sibai; A Bijjani; K Karam
Journal:  Can J Anaesth       Date:  1992-02       Impact factor: 5.063

4.  Prescribing Patterns of Continuous Infusions in Nonobese versus Obese Children Admitted to the Pediatric Intensive Care Unit.

Authors:  Peter N Johnson; Katy Stephens; Philip Barker; Erica Bergeron; Sin Yin Lim; Tracy M Hagemann; Teresa V Lewis; Stephen Neely; Jamie L Miller
Journal:  J Pediatr Intensive Care       Date:  2019-06-21

5.  Neuromuscular effects of vecuronium and neostigmine in Montreal and Paris.

Authors:  Y Salib; J Frossard; B Plaud; B Debaene; C Meistelman; F Donati
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

Review 6.  Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies.

Authors:  Zahid Hussain; Colin Curtain; Corinne Mirkazemi; Syed Tabish Razi Zaidi
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

7.  Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients.

Authors:  Shilpa Bhimasen Joshi; Ks Vasudeva Upadhyaya; M Manjuladevi
Journal:  Indian J Anaesth       Date:  2015-03

Review 8.  A review on the anesthetic management of obese patients undergoing surgery.

Authors:  Rimanatou Seyni-Boureima; Zongze Zhang; Malyn M L K Antoine; Chrystal D Antoine-Frank
Journal:  BMC Anesthesiol       Date:  2022-04-05       Impact factor: 2.217

Review 9.  Qualitative Neuromuscular Monitoring: How to Optimize the Use of a Peripheral Nerve Stimulator to Reduce the Risk of Residual Neuromuscular Blockade.

Authors:  Stephan R Thilen; Sanjay M Bhananker
Journal:  Curr Anesthesiol Rep       Date:  2016-03-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.